1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • HLA genotyping in synovial sarcoma: Identifying HLA-A*02 and its association with clinical outcome
    Meeting Abstract

    Rosenbaum, E.; Seier, K.; Bandlamudi, C.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Nacev, B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Locoregional control, failure patterns and clinical outcomes in patients with stage III non-small cell lung cancers treated with chemoradiation and durvalumab
    Meeting Abstract

    Offin, M.; Shaverdian, N.; Rimner, A.; Lobaugh, S.; Shepherd, A.; Simone, C. B.; Gelblum, D. Y.; Wu, A. J. C.; Lee, N. Y.; Kris, M. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation
    Meeting Abstract

    Mellinghoff, I. K.; Van den Bent, M. J.; Clarke, J. L.; Maher, E. A.; Peters, K. B.; Touat, M.; De Groot, J. F.; De La Fuente, M. I.; Arrillaga-Romany, I.; Wick, W.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers
    Meeting Abstract

    Kirtane, K.; Massarelli, E.; Hanna, G. J.; Klebanoff, C. A.; Blumenschein, G.; Bishop, M. R.; Lee, S.; Niu, J.; Adhikary, S.; Astrow, S. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Joffe, E.; Vardhana, S. A.; Kumar, A.; Abedi, M.; Hoeg, R.; Sharon, E.; Younes, A.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Hepatic arterial infusion (HAI) chemotherapy via the medtronic pump-assessing dose delivery, response rates and toxicity
    Meeting Abstract

    Connell, L. C.; Fiedler, L.; Dickinson, S.; Ly, M.; Harrington, K.; Jarnagin, W. R.; Kingham, T. P.; Drebin, J. A.; Balachandran, V. P.; Wei, A. C.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Buxton, M. B.; Alexander, B. M.; Berry, D. A.; Cavenee, W. K.; Colman, H.; De Groot, J. F.; Ellingson, B. M.; Gordon, G. B.; Khasraw, M.; Lassman, A. B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
    Meeting Abstract

    Yuan, X.; Zhang, X.; Du, R.; Cheung, S. H.; Wei, M.; Zhou, C.; Wang, L.; Shearer, T.; Edris, B.; Smith, M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • CHD1-loss confers AR targeted therapy resistance via promoting cancer heterogeneity and lineage plasticity
    Meeting Abstract

    Zhang, Z.; Zhou, C.; Li, X.; Barnes, S.; Deng, S.; Hoover, E.; Chen, C. C.; Lee, Y. S.; Wang, C.; Tirado, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save